Trulicity has been around long enough that a lot of people assume a cheap generic must exist by now. It doesn't — and the reason is a technicality that changes the whole picture. Trulicity isn't a simple pill; it's a biologic. That single fact rules out a classic generic and routes the conversation toward something called a biosimilar.
Direct answer: The generic name for Trulicity is dulaglutide, but there is no generic Trulicity in 2026 — and there can't be one in the usual sense. Dulaglutide is a biologic (an engineered protein), so the only copy pathway is a biosimilar, not a chemical generic. As of 2026, no dulaglutide biosimilar is approved in the United States. The patents protecting Trulicity run from roughly 2036 to 2038, so US biosimilars are years away. For most patients, the practical answer isn't waiting — it's the savings card or switching to a newer, stronger GLP-1.
Generic vs Biosimilar: Why the Word Matters
A "generic" is an exact chemical copy of a small-molecule drug — metformin, atorvastatin, that kind of thing. Biologics are large, complex proteins grown in living cells, and they can't be copied atom-for-atom. Instead, regulators approve biosimilars: products shown to be highly similar to the original with no clinically meaningful differences. They go through a different, more demanding approval pathway, which is why they take longer and cost more to develop.
| Generic | Biosimilar | |
|---|---|---|
| Applies to | Small-molecule drugs | Biologics (proteins) |
| Copy standard | Identical active ingredient | Highly similar, no meaningful difference |
| Example drug | Metformin, liraglutide | Dulaglutide, insulin, antibodies |
| Trulicity falls here? | No | Yes |
| Typical price cut | 80-90% | 15-35% |
So when you search "Trulicity generic," what you're really asking is whether a dulaglutide biosimilar exists. In 2026, in the US, it does not.
Where the Biosimilar Pipeline Actually Stands
There is real biosimilar activity globally, but it has not reached US patients. The furthest-along program belongs to China's Shandong Boan Biotech. Its dulaglutide biosimilar — branded Boyouping, developed under the codes LY05008/BA5101 — was approved by China's National Medical Products Administration (NMPA) on August 8, 2025. Boan describes it as the first and only biosimilar to Trulicity approved for marketing in the world.
The supporting Phase 3 trial, published in the Journal of Diabetes in April 2025, randomized 440 Chinese adults with type 2 diabetes and found the biosimilar matched the reference Trulicity closely: HbA1c reductions of -1.44% (biosimilar) versus -1.41% (Trulicity), with comparable safety, pharmacokinetics, and immunogenicity.
The catch for US readers: that approval is China-only. No dulaglutide biosimilar has been approved by the FDA, and DrugPatentWatch shows no brand-side biosimilar litigation yet — a sign that no US biosimilar application has advanced far enough to trigger patent disputes. The patents themselves point to a long wait:
| Region/status | Detail |
|---|---|
| US patent expiry (earliest) | ~June 30, 2036 |
| US patent expiry (latest disclosed) | ~June 13, 2038 |
| US biosimilar approved? | No |
| First global biosimilar | Boyouping (China, NMPA, Aug 8, 2025) |
| US biosimilar litigation | None on record |
Bottom line: a US dulaglutide biosimilar is not a 2026 or even near-term reality. Plan as if there is no cheaper copy coming soon.
So What Do You Actually Do About the Price?
If you're on Trulicity for the cost reasons that brought you to this page, there are two real levers — and a third that may matter more than either.
Lever 1 — the savings card. Trulicity's list price is roughly $987/month for a 4-pen, 28-day supply, regardless of dose. If you have commercial drug insurance that covers Trulicity, Lilly's savings card can bring your cost down to as little as $25 for a 1-, 2-, or 3-month fill, subject to monthly and annual caps (up to $150 per 1-month fill, $1,950 per year). It does not apply if you're on Medicare, Medicaid, or other government coverage. We walk through the eligibility fine print in Trulicity coupon.
Lever 2 — wait it out. Realistic, but slow. With US patents into 2036-2038 and no FDA biosimilar in sight, this isn't a 2026 plan.
Lever 3 — switch molecules. This is the one clinicians actually act on. Trulicity is a first-generation weekly GLP-1, and it has been eclipsed by newer drugs that lower A1C and weight more. Many patients who came to Trulicity for blood-sugar control are now moved to semaglutide or tirzepatide, where the cash-pay and discount landscape is more active.
Want a lower price today? Yücca telehealth — online evaluation, doctor-prescribed compounded Tirzepatide+ or Semaglutide+ filled by a licensed US pharmacy, from $146/month. (Partner link: we may earn a commission, at no extra cost to you.)
Is Switching the Real Answer?
For a lot of people, yes. Dulaglutide is effective but middle-of-the-pack by today's standards, and the brands that replaced it have either cash channels (tirzepatide vials) or their own discount routes. Here's how Trulicity sits next to the brands people switch to:
| Brand | Generic name | Cheaper copy in 2026? | Note |
|---|---|---|---|
| Trulicity | Dulaglutide | No (biologic, no US biosimilar) | Savings card or switch |
| Ozempic / Wegovy | Semaglutide | No — Ozempic generic | Stronger A1C/weight effect |
| Mounjaro / Zepbound | Tirzepatide | No — Mounjaro generic / Zepbound generic | Cash vials $299-$449 |
| Saxenda | Liraglutide | Yes — Saxenda generic | True generic available |
Note the irony: the oldest GLP-1 brand here (Saxenda) is the only one with a genuine generic, while Trulicity — also old — can't have one because it's a biologic. If price is the whole reason you're here, talk to your prescriber about whether a switch makes clinical sense before you bank on a biosimilar that isn't coming soon.
Frequently Asked Questions
What is the generic name for Trulicity? Dulaglutide. It's the active ingredient, but because dulaglutide is a biologic, a copy would be a biosimilar rather than a conventional generic.
Is there a generic for Trulicity in 2026? No. There is no generic and no FDA-approved biosimilar in the US. Trulicity's US patents run roughly 2036-2038.
Will there be a Trulicity biosimilar? Eventually, likely. One biosimilar (Boyouping) is already approved in China as of August 2025, but none has been approved in the US, and patent timing puts a US version years out.
Why can't Trulicity have a normal generic? Because dulaglutide is a biologic — a large engineered protein — which can't be copied exactly. Regulators approve "biosimilars" instead, through a longer pathway.
How do I lower my Trulicity cost now? Use the Lilly savings card if you have commercial insurance ($25 fills with caps), or talk to your prescriber about switching to a newer GLP-1 with more discount options.
Last reviewed: June 13, 2026
